Ablynx NV (Nasdaq: ABLX) today announced additional results from the Phase III HERCULES study with caplacizumab, the Company's anti-von Willebrand ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE